Beckley’s 5-MeO-DMT Phase 2b shows rapid, durable antidepressant effects in treatment-resistant depression

5-MeO-DMT in Beckley Psytech’s intranasal program (BPL-003) produced rapid and durable antidepressant effects in a Phase 2b study for treatment-resistant depression. In the study, participants receiving higher doses plus psychological support showed large MADRS score reductions by day 29, including a reported mean decrease of 11.1 points for 12 mg versus 5.8 in the 0.3 mg comparator group. The mid-dose group (8 mg) was also reported to perform slightly better, and the antidepressant effect was described as largely maintained through day 57. Safety results were presented as generally well-tolerated across doses, with no drug-related serious adverse events and no instances of treatment-emergent suicidal intent or behaviour in the mid- and high-dose arms. The piece also compares Beckley’s topline readout to GH Research’s concurrently developed inhaled 5-MeO-DMT approach and highlights differences in trial design, endpoints, and dosing models that may affect interpretation.